Crossmark

Ultrasound responsive erythrocyte membrane-derived hybrid nanovesicles with controlled drug release for tumor therapy

Crossref DOI link: https://doi.org/10.1039/D1NR01916C

Published Online: 2021

Update policy: https://doi.org/10.1039/rsc_crossmark_policy

Authors

Wang, Dongdong https://orcid.org/0000-0001-5272-2011
Yao, Yuzhu https://orcid.org/0000-0001-8846-4472
Xiao, Yi https://orcid.org/0000-0002-2533-5259
Chen, Xue

Hu, Jun https://orcid.org/0000-0002-2568-9030
Yang, Xiangliang https://orcid.org/0000-0003-0683-8763
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81771978)

National Natural Science Foundation of China (82072066)

National Natural Science Foundation of China (81627901)

National Natural Science Foundation of China (82073796)

National Key Research and Development Program of China (2018YFA0208903)

National Key Research and Development Program of China (2020YFA0710700)
License Information

Accepted Manuscript valid from 2022-05-12
More Information

SIMILARITY CHECK

: This document is Similarity Check deposited

RELATED DATA

: Supplementary Information

IDENTIFIERS

: Dongdong Wang (ORCID)

: Yuzhu Yao (ORCID)

: Yi Xiao (ORCID)

: Jun Hu (ORCID)

: Xiangliang Yang (ORCID)

PEER REVIEW METHOD

: Single-blind

PUBLICATION HISTORY

: Received 26 March 2021; Accepted 9 May 2021; Accepted Manuscript published 12 May 2021; Advance Article published 31 May 2021; Version of Record published 10 June 2021